secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001000694-24-000040
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax Q3 revenue $85M, net loss $121M; FDA lifts clinical hold on combo vaccine
--------------------------------------------------------------------------------

- Total revenue $85M (down from $187M YoY); net loss $121M vs $131M; cash $924M as of Sept 30.
- FDA removed clinical hold on COVID-19-influenza combination and stand-alone influenza IND candidates.
- Full-year 2024 revenue guidance cut to $650-700M from $700-800M; product sales now $175-225M.
- Combined R&D/SG&A spend on track; targeting ~$500M in 2025 and ~$350M in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000100069424000040/0001000694-24-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000100069424000040/nvax-20241112.htm
  HTML page:      https://secwatch.observer/filing/0001000694-24-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer